New treatment for a rare genetic condition causing high phosphate levels
Official title: Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia
Funded at Fgf Therapeutics INC. · NIH-11076954 · Data updated 2026-11-12
This study is working on a new treatment for people with hyperphosphatemic familial tumoral calcinosis (hfTC), a rare condition that causes high phosphate levels in the body, and aims to help manage these levels and reduce painful lumps to improve your quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fgf Therapeutics INC. NIH-funded |
| Lab location | 1 site (Zionsville, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $231,003 |
| NIH project number | 6R41AR084025-02 |
| Project ID | NIH-11076954 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hyperphosphatemic familial tumoral calcinosis, particularly those experiencing significant symptoms.
✕Less likely to help
Patients without hfTC or those with other forms of hyperphosphatemia unrelated to FGF23 deficiency may not benefit from this research.
What this research studies
This research focuses on developing a novel therapy for hyperphosphatemic familial tumoral calcinosis (hfTC), a rare genetic disorder that leads to dangerously high levels of phosphate in the body. Patients with hfTC cannot produce an important hormone, FGF23, which helps regulate phosphate levels. The research aims to create a treatment that can effectively manage phosphate levels and reduce painful calcifications that can severely impact patients' quality of life. The approach involves innovative methods to replace or mimic the action of FGF23, addressing a significant unmet medical need.
Why it matters
Potential benefit: If successful, this research could provide a much-needed treatment option for patients suffering from hfTC, potentially alleviating pain and preventing severe complications.
How similar studies have gone: While there is limited research specifically targeting hfTC, the approach of developing therapies for hormone deficiencies has shown promise in other conditions, indicating potential for success.
Where this research is happening
-
Fgf Therapeutics INC.
Zionsville, United States Active
Researchers
- Principal investigator: White, Kenneth E — Fgf Therapeutics INC.
- Study coordinator: White, Kenneth E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.